4.7 Article

Hemoglobin level in older persons and incident Alzheimer disease Prospective cohort analysis

Journal

NEUROLOGY
Volume 77, Issue 3, Pages 219-226

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318225aaa9

Keywords

-

Funding

  1. NIH/NIA [R01AG17917, R01AG24480]
  2. Illinois Department of Public Health
  3. Robert C. Borwell Endowment Fund
  4. Ceregene
  5. Danone Research B.V.
  6. Eisai Inc.
  7. Elan Corporation
  8. Merck Co., Inc.
  9. Orasi Medical, Inc.
  10. Pamlab
  11. L.L.C.
  12. Pfizer Inc
  13. NIH
  14. Illinois Department of Public Aid Alzheimer's Disease Assistance Center
  15. NIH (NIA, NINDS)
  16. Danone Inc

Ask authors/readers for more resources

Objective: To test the hypothesis that level of hemoglobin is associated with incident Alzheimer disease (AD). Methods: A total of 881 community-dwelling older persons participating in the Rush Memory and Aging Project without dementia and a measure of hemoglobin level underwent annual cognitive assessments and clinical evaluations for AD. Results: During an average of 3.3 years of follow-up, 113 persons developed AD. In a Cox proportional hazards model adjusted for age, sex, and education, there was a nonlinear relationship between baseline level of hemoglobin such that higher and lower levels of hemoglobin were associated with AD risk (hazard ratio [HR] for the quadratic of hemoglobin 1.06, 95% confidence interval [CI] 1.01-1.11). Findings were unchanged after controlling for multiple covariates. When compared to participants with clinically normal hemoglobin (n = 717), participants with anemia (n = 154) had a 60% increased hazard for developing AD (95% CI 1.02-2.52), as did participants with clinically high hemoglobin (n = 10, HR 3.39, 95% CI 1.25-9.20). Linear mixed-effects models showed that lower and higher hemoglobin levels were associated with a greater rate of global cognitive decline (parameter estimate for quadratic of hemoglobin = -0.008, SE -0.002, p < 0.001). Compared to participants with clinically normal hemoglobin, participants with anemia had a -0.061 z score unit annual decline in global cognitive function (SE 0.012, p < 0.001), as did participants with clinically high hemoglobin (-0.090 unit/year, SE 0.038, p = 0.018). Conclusions: In older persons without dementia, both lower and higher hemoglobin levels are associated with an increased hazard for developing AD and more rapid cognitive decline. Neurology (R) 2011;77:219-226

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available